Kaleido Biosciences Inc

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added to supportive self-care (SSC) in outpatients with mild-to-moderate COVID-19 disease. Updated projections for enrollment of the multi-center K031 clinical study of approximately 350 patients indicated that top-line data will be available in the first quarter of 2021. Previous projections had indicated the potential availability of top-line data from the study in the fourth quarter of 2020.

Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that Daniel Menichella has been appointed President and Chief Executive Officer and a member of the company’s Board of Directors, effective October 13, 2020. Mr. Menichella succeeds Alison Lawton, who stepped down to attend to a family health matter but continued to work with the Company in the Office of the CEO alongside Executive Chair Mike Bonney.

Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer

Why Kaleido Stock Is Taking Off, And Why It Can Go Higher

Top-line safety, tolerability and activity results expected in mid-2021 Top-line safety, tolerability and activity results expected in mid-2021

Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis

LEXINGTON, Mass., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcoming conferences in September. Each conference will involve a fireside chat presentation.

Kaleido Biosciences to Present at Upcoming September Investor Conferences

LEXINGTON, Mass., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic encephalopathy (HE) will be featured during The Digital International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL). The results include details on the effects of KB174 on microbiome nitrogen metabolism in a clinical study in patients with well-compensated cirrhosis, the demonstration of improved tolerability for KB174 relative to lactulose in a study of healthy volunteers, as well as effects of MMTs on bacterial composition in patient samples ex vivo.

Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy at The Digital  International Liver Congress™ (EASL)

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 -

Kaleido Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population -

Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19

Axcella Health Inc

CytomX Therapeutics

Magenta Therapeutics Inc

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 4 Red-Hot Biotech Stocks to Buy Under $10

- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter

Kaleido Biosciences Announces CEO Leadership Transition

LEXINGTON, Mass., June  08, 2020  (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that in light of the COVID-19 pandemic, its 2020 Annual Meeting of Stockholders will now be held solely by live webcast to comply with public health recommendations and protect the health of employees, Stockholders and directors. Stockholders will no longer be able to attend the Annual Meeting in person.

Kaleido Biosciences Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

Kaleido Biosciences, Inc. (KLDO) CEO Alison Lawton on Q1 2020 Results - Earnings Call Transcript

- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 -

Kaleido Biosciences Provides Corporate Update and Reports First Quarter 2020 Financial Results

- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -

Kaleido Biosciences Initiates Controlled Clinical Study of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19

LEXINGTON, Mass., April  03, 2020  (GLOBE NEWSWIRE) --  Kaleido Biosciences, Inc.  (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors. Dr. Prener has more than 25 years of leadership experience within life sciences companies, and recently served as Chief Executive Officer (CEO) of Freeline Ltd.

Kaleido Biosciences Appoints Anne Prener, M.D., Ph.D., to its Board of Directors

Is  (KLDO) Outperforming Other Medical Stocks This Year?

Is Kaleido Biosciences (KLDO) Stock Outpacing Its Medical Peers This Year?

Amarin Corporation Plc

Bristol-Myers

Blackstone Group

Clovis Oncology

Journey Medical Corp

Intuitive Surgical

Johnson & Johnson

Eli Lilly

Medtronic

Roche Holding AG

Sanofi

Sorrento Therapeutics Inc

The Super Bowl of healthcare kicked off early for these companies.

All the 2020 Pre-JPM News Healthcare Investors Need to Know

LEXINGTON, Mass., Jan.  09, 2020  (GLOBE NEWSWIRE) --  Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the initiation of a research collaboration with Janssen’s World Without Disease Accelerator*, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration will explore the potential for Kaleido’s Microbiome Metabolic Therapies (MMT™) to prevent the onset of childhood allergy and other atopic, immune and metabolic conditions by driving specific microbiome features which support an appropriate maturation of the infant immune system. The agreement was facilitated by Johnson & Johnson Innovation.

Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions by Promoting Healthy Function of the Gut Microbiome

News for Kaleido Biosciences Inc Stock (KLDO)